Physician profile
Richard Faraday
NPI 1881662021
$966.98
in general payments reported to CMS, 2019-2025
6 companies · $24.84 in 2025
The $24.84 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $53.67 · 2021: $28.48 · 2025: $24.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $24.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $24.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $253.64 | 2019-2020 | |
| Astellas Pharma US INC | $240.88 | 2019 | |
| Merck Sharp & Dohme LLC | $216.45 | 2019-2020 | |
| Gilead Sciences, INC. | $203.51 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Janssen Biotech, INC. | $24.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Faraday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.